

( (S (NP-SBJ Three leading drug companies)
     (VP reported
         (NP (NP robust third-quarter earnings)
             ,
             (VP bolstered
                 (NP *)
                 (PP by
                     (NP-LGS (NP strong sales)
                             (PP of
                                 (NP (NP newer , big-selling
                                         prescriptions drugs)
                                     (SBAR (WHNP-1 that)
                                           (S (NP-SBJ *T*-1)
                                              (VP provide
                                                  (NP hefty profit margins)))))))))))
     .))
( (S (S (NP-SBJ Merck & Co.)
        (VP reported
            (NP (NP a (ADJP 25 %) increase)
                (PP-LOC in
			(NP earnings)))))
     ;
     (S (S (NP-SBJ (NP Warner-Lambert Co. 's)
		   profit)
	   (VP rose
	       (NP-EXT 22 %)))
	and
	(S (NP-SBJ (NP Eli Lilly & Co. 's)
		   net income)
	   (VP rose
	       (NP-EXT 24 %))))
     .))
( (S (NP-SBJ The results)
     (VP were
         (PP-PRD in
                 (NP (NP line)
                     (PP with
                         (NP (NP analysts ')
                             expectations)))))
     .))
( (NP-HLN Merck & Co .))
( (S (NP-SBJ-1 (NP Merck)
	       ,
	       (NP-LOC (NP Rahway)
		       ,
		       (NP N.J.))
	       ,)
     (VP continued
         (S (NP-SBJ *-1)
            (VP to
                (VP lead
                    (NP the industry)
                    (PP with
                        (NP (NP a strong sales performance)
                            (PP-LOC in 
				    (NP the human and animal health-products segment))))))))
     .))
( (S (NP-SBJ A stronger U.S. dollar)
     (VP reduced
         (NP third-quarter and first-nine-month sales growth)
         (NP-EXT (NP (QP 2 %
			 and
			 3 %)
		     *U*)
		 ,
		 (ADVP respectively)))
     .))
( (S (NP-SBJ International sales)
     (VP accounted
         (PP-CLR for
		 (NP (NP 47 %)
		     (PP of
			 (NP (NP total company sales)
			     (PP for
				 (NP the nine months))))))
	 ,
	 (PP compared
	     (PP with
		 (NP 50 %)
		 (ADVP-TMP (NP a year)
			   earlier))))
     .))
( (S (NP-SBJ (NP Sales)
             (PP for
                 (NP the quarter)))
     (VP rose
         (PP-DIR to
		 (NP (QP $ 1.63 billion) *U*))
         (PP-DIR from
		 (NP (QP $ 1.47 billion) *U*)))
     .))
( (S (S-TPC-1 (NP-SBJ (NP Mevacor)
		      ,
		      (NP (NP Merck 's)
			  new cholesterol-lowering drug)
		      ,)
	      (VP had
		  (NP (NP higher sales)
		      (SBAR than
			    (S (NP-SBJ any other prescription medicine)
			       (VP has
				   (ADVP-TMP ever)
				   (VP achieved
				       (PP-LOC in
					       (NP the U.S.))
				       (PP-TMP in
					       (NP (NP the year)
						   (PP following
						       (NP introduction)))))))))))
     ,
     (NP-SBJ the company)
     (VP said
	 (SBAR 0
	       (S *T*-1)) )
     .))
( (S (NP-SBJ-1 The drug)
     (VP was
         (VP introduced
             (NP *-1)
	     (PP-LOC-CLR in
			 (NP West Germany))
	     (NP-TMP this year)))
     .))
( (S (NP-SBJ Intense competition)
     ,
     (ADVP however)
     ,
     (VP led
         (PP-DIR to
		 (NP (NP unit sales declines)
		     (PP for
			 (NP (NP (NP a group)
				 (PP of
				     (NP (NP Merck 's)
					 established human and animal-health products)))
			     ,
			     (PP including
				 (NP Aldomet and Indocin)))))))
     .))
( (S (PP-LOC In
	     (NP New York Stock Exchange composite trading))
     (NP-TMP yesterday)
     ,
     (NP-SBJ Merck shares)
     (VP closed
         (PP-CLR at
		 (NP $ 75.25 *U*))
         ,
         (ADVP up
               (NP 50 cents)))
     .))
( (NP-HLN Warner-Lambert Co .))
( (S (NP-SBJ (NP Warner-Lambert)
             ,
             (NP (NP Morris Plains)
                 ,
                 (NP N.J.)
                 ,))
     (VP reported
         (NP (NP sales)
             (SBAR (WHNP-1 that)
                   (S (NP-SBJ *T*-1)
                      (VP were
                          (NP-PRD (NP (NP a record)
                                      (PP for
                                          (NP any quarter)))
                                  and
                                  (NP (NP the eighth quarter)
                                      (PP in
                                          (NP a row))
                                      (PP of
                                          (NP (QP 20 %
						  or
						  more)
                                              per-share earnings growth)))))))))
     .))
( (S (S-ADV (NP-SBJ *-1)
	    (VP Spurred
		(PP by
		    (NP-LGS (NP growth)
			    (PP-LOC in
				    (NP (NP world-wide sales)
					(PP of
					    (NP (NP the company 's)
						prescription drugs))))))))
     ,
     (NP-SBJ-1 Warner-Lambert)
     (VP said
	 (SBAR 0
	       (S (NP-SBJ 1989)
		  (VP will
		      (VP be
			  (NP-PRD (NP the best year)
				  (PP-TMP in
					  (NP its history)))
			  ,
			  (SBAR with
				(S (NP-SBJ-2 per-share earnings)
				   (VP expected
				       (S (NP-SBJ *-2)
					  (VP to
					      (VP increase
						  (NP (QP more
							  than
							  20)
						      %)
						  (PP-DIR to
							  (NP (QP about $ 6.10) *U*)))))))))))))
     .))
( (S (NP-SBJ (NP Sales)
             (PP for
                 (NP the quarter)))
     (VP rose
         (PP-DIR to
		 (NP (QP $ 1.11 billion) *U*))
         (PP-DIR from
		 (NP (QP $ 1.03 billion) *U*)))
     .))
( (S (S (NP-SBJ Prescription-drug world-wide sales)
        (VP rose
            (NP-EXT 9 %)
            (PP-TMP in
		    (NP the quarter))
            (PP-DIR to
		    (NP (QP $ 340 million) *U*))))
     ;
     (S (NP-SBJ U.S. sales)
        (VP rose
            (NP-EXT 15 %)))
     .))
( (S (NP-SBJ-1 (NP The segment 's)
               growth)
     (VP was
         (VP led
             (NP *-1)
             (PP by
                 (NP-LGS (NP sales)
			 (PP of
			     (NP (NP the cardiovascular drugs)
				 (NP (NP (NP Lopid)
					 ,
					 (NP a lipid regulator))
				     , and
				     (NP (NP Dilzem)
					 ,
					 (NP a calcium channel blocker)))))))))
     .))
( (S (S (NP-SBJ (NP World-wide sales)
                (PP of
                    (NP (NP (NP Warner-Lambert 's)
                            non-prescription health-care products)
                        ,
                        (PP such as
                            (NP (NP Halls cough tablets)
                                ,
                                (NP Rolaids antacid)
                                , and
                                (NP Lubriderm skin lotion)))
                        ,)))
        (VP increased
            (NP-EXT 3 %)
            (PP-DIR to
		    (NP (QP $ 362 million) *U*))
            (PP-TMP in
		    (NP the third quarter))))
     ;
     (S (NP-SBJ U.S. sales)
        (VP rose
            (NP-EXT 5 %)))
     .))
( (S (NP-SBJ Confectionery products sales)
     (ADVP also)
     (VP had
         (NP strong growth)
	 (PP-TMP in
		 (NP the quarter)))
     .))
( (S (NP-SBJ (NP World-wide sales)
             (PP of
                 (NP (NP Trident gum)
                     ,
                     (NP Certs breath mints)
                     , and
                     (NP Clorets gum and breath mints)
                     ,)))
     (VP increased
         (NP-EXT 12 %)
         (PP-DIR to
		 (NP (QP $ 277 million) *U*)))
     .))
( (S (NP-SBJ Warner-Lambert shares)
     (VP closed
         (PP-CLR at
		 (NP (NP $ 109.50 *U*)
		     (NP-ADV a share)))
         ,
         (ADVP up
               (NP $ 1.50 *U*))
	 ,
	 (PP-LOC in
		 (NP Big Board composite trading))
	 (NP-TMP yesterday))
     .))
( (NP-HLN Eli Lilly & Co .))
( (S (NP-SBJ Lilly)
     (VP attributed
         (NP record third-quarter and nine-month results)
         (PP-CLR to
		 (NP (NP world-wide gains)
		     (PP for
			 (NP (NP pharmaceuticals)
			     ,
			     (NP medical instruments)
			     and
			     (NP plant-science products)))
		     (PP despite
			 (NP (NP (NP poor exchange rates)
				 (PP for
				     (NP the dollar)))
			     (SBAR (WHNP-1 that)
				   (S (NP-SBJ *T*-1)
				      (VP slowed
					  (NP (NP sales) 
					      (ADVP-LOC abroad)))))))))) 
     .))
( (S (NP-SBJ-1 Earnings)
     (VP continued
         (S (NP-SBJ *-1)
            (VP to
                (VP pace
                    (NP sales))))
	 (PP-PRP because of
		 (NP (NP a lower tax rate)
		     ,
		     (NP (NP profit)
			 (PP from
			     (NP (NP the renegotiation)
				 (PP of
				     (NP (NP the debt instrument)
					 (VP received
					     (NP *)
					     (PP-CLR from
						     (NP Faberge Inc.))
					     (PP in
						 (NP (NP connection)
						     (PP with
							 (NP (NP (NP Lilly 's)
								 sale)
							     (PP of
								 (NP Elizabeth Arden Inc.))
							     (PP-TMP in
								     (NP 1987))))))))))))
		     , and
		     (NP (NP net proceeds)
			 (PP from
			     (NP (NP the settlement)
				 (PP of
				     (NP patent litigation))
				 (PP-LOC at
					 (NP (NP Lilly 's)
					     Hybritech Inc. unit))))))))
     .))
( (S (NP-SBJ (NP Third-quarter sales)
             (PP of
                 (NP the
                     (NAC-LOC Indianapolis
			      ,
			      Ind.
			      ,)
                     company)))
     (VP rose
         (NP-EXT 11 %)
         (PP-DIR to
		 (NP (QP $ 1.045 billion) *U*))
         (PP-DIR from
		 (NP (QP $ 940.6 million) *U*)))
     .))
( (S (NP-SBJ Nine-month sales)
     (VP grew
         (NP-EXT 12 %)
         (PP-DIR to
		 (NP (QP $ 3.39 billion) *U*))
         (PP-DIR from
		 (NP (QP $ 3.03 billion)
		     *U*)
		 (ADVP-TMP (NP a year)
			   earlier)))
     .))
( (S (NP-SBJ (NP Sales)
             (PP of
                 (NP (NP Prozac)
                     ,
                     (NP an anti-depressant)
                     ,)))
     (VP led
         (NP drug-sales increases))
     .))
( (S (S-TPC-1 (NP-SBJ (NP Higher sales)
		      (PP of
			  (NP (NP pesticides)
			      and
			      (NP other plant-science products))))
	      (VP (ADVP more than) 
		  offset
		  (NP (NP a slight decline)
		      (PP-LOC in
			      (NP (NP the sales)
				  (PP of
				      (NP animal-health products)))))
		  (S-CLR (NP-SBJ *) 
			 (VP to
			     (VP fuel
				 (NP (NP the increase)
				     (PP-LOC in
					     (NP world-wide agricultural product sales))))))))
     ,
     (NP-SBJ Lilly)
     (VP said
	 (SBAR 0
	       (S *T*-1)) )
     .))
( (S (NP-SBJ (NP Advanced Cardiovascular Systems Inc.)
             and
             (NP Cardiac Pacemakers Inc. units))
     (VP led
         (NP (NP growth)
             (PP-LOC in
		     (NP the medical-instrument systems division))))
     .))
( (S (NP-SBJ Lilly shares)
     (VP closed
         (NP-TMP yesterday)
         (PP-LOC in
		 (NP (NP composite trading)
		     (PP-LOC on
			     (NP the Big Board))))
         (PP-CLR at
		 (NP $ 62.25 *U*))
	 ,
	 (ADVP down
	       (NP 12.5 cents)))
     .))
